Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Read more

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

Read more

IPO

IPO Calliditas Therapeutics

Read more

Press releases

• Jan 14, 2019Calliditas Therapeutics appoints Frank Bringstrup as VP Regulatory Affairs
• Jan 8, 2019Calliditas Therapeutics appoints Andrew Udell to VP Commercial, North America
• Dec 14, 2018Bulletin from extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ)

All press releases

Interim Report Q3 2018

On November 1, 2018, Calliditas Therapeutics published its interim report for the third quarter of 2018.

• Report
• Press release
• Presentation
• Audio cast

Read the report

Calendar

• Feb 7, 2019Year-end report for the period January 1 – December 31, 2018
• May 8, 2019Annual general meeting 2019
• May 8, 2019Interim report for the period January 1 – March 31, 2019

All events